

FINAL
University of Washington
Institutional Biosafety Committee (IBC)

Date: Friday February 2, 2007
Time: 1:00 - 3:00 pm
Location: HSB T-269

Meeting Minutes

Members Present: Thea Brabb, Comparative Medicine
David Emery (IBC Chair), Medical Genetics
Mary Lampe, Laboratory Medicine
Steve Libby, Laboratory Medicine
Glenn McLean, Research & Biological Safety
Pamela Morris, Comparative Medicine
David Russell, Hematology
Carol Sibley, Genome Sciences
Valerie Yerkes, Community Member

Members Absent: Michael Agy, Washington National Primate Research Center
William Atkins, Medicinal Chemistry
Ashley Fleischman, ASUW Student Representative
Kimball Jones, Community Member
Elaine Jong, Hall Health Primary Care Center/UW Campus Health Services
Paul Swenson, Community Member
James Woods, Environmental & Occupational Health Sciences
Estella Whimbey, Healthcare Epidemiology and Infection Control

Guests: Debra Durham, Community Guest
Greg Hunter, Research & Biological Safety
JoAnn Kauffman, Research & Biological Safety
Mike McCormick, Community Guest

Handouts: Agenda
November 17, 2006 Draft Meeting Minutes
Biosafety Officer Reports: Don Wang, Glenn McLean, Eric Stefansson
Recommendation Summary: Michael Gale's Research
Membership Roster

1. CALL TO ORDER

1a. Chair, David Emery, called the meeting to order at 1:08 p.m.

2. APPROVAL OF MINUTES from the November 17, 2006 IBC Meeting

2a. Minutes from the Nov. 17, 2006 meeting were submitted to the members for approval.

Vote called to approve minutes from November 17, 2006: Unanimous approval.

3. ADMINISTRATIVE & INFORMATIONAL UPDATES

3a. Personnel Updates:

David Emery, informed the committee of the following personnel changes in the Research & Biological Safety Office:

JoAnn Kauffman – Manager, Office of Research & Biological Safety

Greg Hunter – Associate Biosafety Officer, Office of Research & Biological Safety

3b. 2007 Meeting Schedule:

May 11, 2007

September 7, 2007

3c. BSO IBC membership:

The committee discussed additional BSO membership on the IBC. Chairman, David Emery, ruled BSO membership on the IBC will remain at the discretion the Institutional Official and the RBSO manager.

4. OLD BUSINESS AND ACTION ITEM REVIEW

- 4a. David Emery updated the committee on the development of improved methods of communication between the RBSO and the University research community.

5. SUB COMMITTEE REPORT: Michael Gale's Research

- 5a. Dave Emery presented the IBC subcommittee review and recommendations for Michael Gale's proposed research. Committee moved to edit the purpose section of the subcommittee review summation document to reflect that BSL 3 containment is required for large scale propagation of HIV and briefly debated what criteria the committee should use to determine what constitutes a large quantity. The committee settled on the regulatory limit of ten liters.

Vote called to approve the Michael Gale's research per the sub-committee recommendations:
Unanimously approved

6. SPECIFIC RESEARCH PROPOSALS

6a. Don Wang, Biosafety Officer's report:

1. BSO approvals for Sandra Bordin and Beverly Dale-Clark were discussed. Members of the committee suggested a reduction in biosafety requirements for work with *Porphyromonas gingivalis* from BSL/ABSL 2 to 1. Chairman, David Emery, called for sub-committee review of biosafety for *P. gingivalis*.

Vote called to approve Don Wang's BSO report with noted exception: Unanimously approved

6b. Eric Stefansson, Biosafety Officer's report:

1. BSO approval for Stuart Strand's research was discussed. Members of the committee voiced concerns over possible environmental release of transgenic grasses. JoAnn Kauffman, manager of RBSO, briefly explained the nomenclature used by NIH Guidelines for Recombinant DNA to address plant containment. BSL2-P was prescribed because of the use of grasses. In addition to facility containment in place, PI Strand will institute the use of a bio-bubble for plant housing and institute practices for effective containment such as the covering of plants with bags during flowering and the prompt destruction of all flowers prior to maturity. These methods were considered adequate controls and the research approval was upheld by the committee.

Vote called to approve Eric Stefansson's BSO report: Unanimously approved

6c. Glenn McLean, Biosafety Officer's report:

1. BSO approvals for William Parks, Samuel Moskowitz, and Saman Arbabi were discussed. The committee recommended a reduction in the biosafety level for work with *Pseudomonas aeruginosa* from BSL/ABSL 2 to 1. David Emery called for sub-committee review of biosafety for

Pseudomonas aeruginosa to be conducted in conjunction with the sub-committee review of *Porphyromonas gingivalis*.

2. BSO report on William Osborne was addressed. The committee would like the reference to "lentivirus" in the BSO report be changed to "lentiviral vectors" to more accurately represent the research.
3. BSO approval for Shawn Skerrett was discussed. The committee suggested a reduction in biosafety requirements for work with *Burkholderia thailandensis* from BSL/ABSL 2 to 1. David Emery called for sub-committee review of *Burkholderia thailandensis* biosafety to be included with the review of *Pseudomonas aeruginosa* and *Porphyromonas gingivalis*.
4. BSO approval for Carol Ware was discussed. Concerns were voiced by committee members on the appropriate decontamination methods for prions and whether there are adequate methods for verification of decontamination. Glenn McLean addressed some of these issues by sighting literature and the BMBL to justify the current decontamination methods in place. David Emery called for sub-committee review of prion decontamination to more fully address this concern.

Vote called to approve Glenn McLean's BSO report with noted exceptions: Unanimously approved

7. ISSUES FROM THE FLOOR

1. David Emery presented a report to the committee on the accidental release of one transgenic mouse from ABSL 2 housing. The transgenic line was engineered to facilitate a diabetic condition in the mouse upon the introduction LCMV, no hazardous biotoxins or oncogenes were being expressed in the mouse. This loss of containment has been interpreted as a reportable incident per NIH guidelines. The RBSO manager is in the process of preparing a formal report to the NIH Office of Biotechnology.
2. David Emery addressed the committee for its input on the perceived effectiveness of sealing biological safety cabinets with shrink wrap as an effective alternative to formalin decontamination for certain biological safety cabinet relocations. The consensus of the committee was that the shrink wrap method could be acceptable for cabinet relocations within the same building, but each situation should be reviewed by a HVAC safety committee on a case-by-case basis.

Meeting Adjourned at 2:21 pm.

Meeting Minutes by GH